Suven Life Sciences Limited Stock Price Today (NSE: SUVEN)
Suven Life Sciences Limited
Fundamental Score
Suven Life Sciences Limited Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Suven Life Sciences Limited share price today is ₹336.45, up +0.90% on NSE/BSE as of 16 September 2026. Suven Life Sciences Limited (SUVEN) is a Mid-cap company in the Healthcare Research, Analytics & Technology sector with a market capitalisation of ₹8.88K (Cr). The 52-week high for SUVEN share price is ₹403.35 and the 52-week low is ₹124.11. The company has a Return on Equity (ROE) of -78.80% and a debt-to-equity ratio of 0.00.
Suven Life Sciences Limited Share Price Chart — NSE/BSE Historical Performance
Suven Life Sciences Limited share price chart: 7.49% return over the past month. 52-week high ₹403.35, 52-week low ₹124.11.
Suven Life Sciences Limited — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹335.00 | ₹342.00 | ₹324.00 | ₹336.45 | 5.21L (Cr) | |
| ₹356.35 | ₹363.95 | ₹327.10 | ₹333.45 | 8.71L (Cr) | |
| ₹355.00 | ₹359.95 | ₹351.50 | ₹355.55 | 3.70L (Cr) | |
| ₹357.75 | ₹366.70 | ₹357.75 | ₹360.70 | 2.97L (Cr) | |
| ₹369.90 | ₹376.75 | ₹355.05 | ₹357.50 | 7.80L (Cr) | |
| ₹376.45 | ₹380.00 | ₹368.00 | ₹369.90 | 4.69L (Cr) | |
| ₹378.70 | ₹395.40 | ₹376.10 | ₹377.15 | 8.62L (Cr) | |
| ₹382.00 | ₹388.45 | ₹376.70 | ₹378.00 | 4.95L (Cr) | |
| ₹374.00 | ₹391.00 | ₹367.75 | ₹378.35 | 16.93L (Cr) | |
| ₹379.00 | ₹387.95 | ₹370.10 | ₹372.85 | 5.56L (Cr) |
Suven Life Sciences Limited — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹394.00 | ₹403.35 | ₹324.00 | ₹336.45 | -14.61% | |
| ₹307.25 | ₹395.00 | ₹300.00 | ₹392.05 | +27.60% | |
| ₹280.65 | ₹371.00 | ₹272.20 | ₹307.10 | +9.42% | |
| ₹297.95 | ₹297.95 | ₹230.60 | ₹280.65 | -5.81% | |
| ₹211.84 | ₹294.88 | ₹200.00 | ₹279.34 | +31.86% | |
| ₹139.50 | ₹229.69 | ₹135.50 | ₹211.88 | +51.89% | |
| ₹140.00 | ₹148.00 | ₹124.11 | ₹131.70 | -5.93% | |
| ₹139.90 | ₹176.02 | ₹131.63 | ₹146.07 | +4.41% | |
| ₹166.50 | ₹178.50 | ₹125.45 | ₹132.81 | -20.23% | |
| ₹172.50 | ₹183.80 | ₹160.20 | ₹166.27 | -3.61% | |
| ₹198.37 | ₹207.01 | ₹166.55 | ₹172.14 | -13.22% | |
| ₹204.21 | ₹216.79 | ₹186.00 | ₹197.55 | -3.26% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Suven Life Sciences Limited Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Suven Life Sciences Limited Fundamental Analysis & Valuation Benchmarking
Educational evaluation of SUVEN across key market metrics for learning purposes.
Positive Indicators
5 factors identified
Strong Revenue Growth (91.02%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Debt-Free Balance Sheet (D/E: 0.00)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Healthy Liquidity Position (Current Ratio: 3.21)
Observation: Strong short-term liquidity to meet obligations.
Analysis: Current ratio >1.5 indicates good working capital management.
Balanced Promoter Holding (67.36%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
9 factors identified
Below-Average Return on Equity (-78.80%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (-78.35%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Margin Pressure Concerns (-1830.23%)
Observation: Operating margins are below industry standards.
Analysis: OPM <5% may indicate pricing pressures or cost management challenges.
High Price-to-Book Ratio (66.71x)
Observation: Trading at significant premium to book value.
Analysis: High P/B ratios may indicate overvaluation relative to asset base.
Limited Growth History (-12.00% CAGR)
Observation: Below-average 5-year sales growth trajectory.
Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities.
Weak Interest Coverage (-1750.23x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability.
Negative Free Cash Flow (₹-847.05 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
Limited Institutional Interest (FII+DII: 5.53%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Suven Life Sciences Limited vs Healthcare Research, Analytics & Technology Peers
Peer Comparison - Healthcare Research, Analytics & Technology
Compare Suven Life Sciences Limited with 8 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Suven Life Sciences LimitedSuven Life Scie...Selected✓ SUVEN • 530239 | 11.4/100 | ₹336.45₹336 | ₹8882.04₹8882.04 | — — | -78.80%Poor -78.80% Poor | -78.35%Poor -78.35% Poor | 0.00Excellent 0.0 Excellent | — — | -12.00%Poor -12.00% Poor | 0.00% |
Syngene International LimitedSyngene Interna... SYNGENE • 539268 | 35.4/100 | ₹386.80₹387 | ₹15615.12₹15615.12 | 70.33Average 70.3 Average | 0.00%Poor 0.00% Poor | 8.43%Poor 8.43% Poor | 0.00Excellent 0.0 Excellent | -0.98%Poor -0.98% Poor | 11.35%Good 11.35% Good | 0.30% |
Indegene LimitedIndegene Limite... INDGN • 544172 | 57/100 | ₹586.35₹586 | ₹14101.72₹14101.72 | 35.09Average 35.1 Average | 13.94%Average 13.94% Average | 17.29%Good 17.29% Good | 0.00Excellent 0.0 Excellent | 23.02%Excellent 23.02% Excellent | 29.44%Excellent 29.44% Excellent | 0.39% |
Vimta Labs LimitedVimta Labs Limi... VIMTALABS • 524394 | 63.6/100 | ₹628.15₹628 | ₹2805.95₹2805.95 | 35.17Average 35.2 Average | 18.55%Good 18.55% Good | 23.39%Excellent 23.39% Excellent | 0.01Excellent 0.0 Excellent | 29.35%Excellent 29.35% Excellent | 14.09%Good 14.09% Good | 0.35% |
TAKE LimitedTAKE Limited... TAKE • 532890 | 31.2/100 | ₹15.99₹16 | ₹236.55₹236.55 | 18.59Average 18.6 Average | 42.11%Excellent 42.11% Excellent | 18.49%Good 18.49% Good | 0.00Excellent 0.0 Excellent | 15.08%Excellent 15.08% Excellent | -41.25%Poor -41.25% Poor | 0.00% |
NOVELIX PHARMACEUTICALS LIMITENOVELIX PHARMAC... NOVELIX • 536565 | 56.9/100 | ₹78.10₹78 | ₹164.67₹164.67 | 45.33Average 45.3 Average | 8.00%Poor 8.00% Poor | 9.96%Poor 9.96% Poor | 0.09Excellent 0.1 Excellent | 22.72%Excellent 22.72% Excellent | 151.69%Excellent 151.69% Excellent | 0.00% |
Bilcare LimitedBilcare Limited... BI • 526853 | 28.9/100 | ₹91.66₹92 | ₹147.94₹147.94 | 26.80Average 26.8 Average | 1.66%Poor 1.66% Poor | 5.56%Poor 5.56% Poor | 3.15Poor 3.1 Poor | 16.32%Excellent 16.32% Excellent | 3.33%Average 3.33% Average | 0.00% |
Adeshwar Meditex LtdAdeshwar Medite... ADESHWAR • 543309 | 24.6/100 | ₹16.30₹16 | ₹23.52₹23.52 | 19.47Average 19.5 Average | 3.38%Poor 3.38% Poor | 6.02%Poor 6.02% Poor | 0.16Excellent 0.2 Excellent | -6.68%Poor -6.68% Poor | -3.19%Poor -3.19% Poor | 0.00% |
Vanta Bioscience LtdVanta Bioscienc... VANTABIO • 540729 | 23.9/100 | ₹19.60₹20 | ₹13.94₹13.94 | 163.55Average 163.6 Average | 0.76%Poor 0.76% Poor | 1.39%Poor 1.39% Poor | 1.80Average 1.8 Average | -24.21%Poor -24.21% Poor | -28.62%Poor -28.62% Poor | 0.00% |
Top Healthcare Research, Analytics & Technology Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Syngene International Limited share price15615.12 Cr
- Indegene Limited share price14101.72 Cr
- Vimta Labs Limited share price2805.95 Cr
- TAKE Limited share price236.55 Cr
- NOVELIX PHARMACEUTICALS LIMITE share price164.67 Cr
Suven Life Sciences Limited Quarterly Performance
Latest quarterly metrics for SUVEN — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
91.02%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
-3.78%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
-12.00%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
N/A
Compounded annual net profit growth over 5 years
Suven Life Sciences Limited Technical Indicators
SMA 50, SMA 200, RSI and volume signals for SUVEN — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Suven Life Sciences Limited Financial Statements
Annual income statement, balance sheet and cash flow for Suven Life Sciences Limited (SUVEN) — sourced from NSE/BSE filings.
Financial Results & Statements
Latest quarterly, annual and period-wise financial data for Suven Life Sciences Limited
About SUVEN (Suven Life Sciences Limited)
Suven Life Sciences Ltd is a pioneering force in the healthcare sector, operating at the intersection of cutting-edge research, advanced analytics, and transformative technology. T...he company dedicates its efforts to unraveling the complexities of neurodegenerative diseases, particularly those affecting the central nervous system. Through rigorous scientific investigation and innovative drug discovery processes, Suven aims to identify and develop novel therapeutic interventions with the potential to significantly improve the lives of patients suffering from conditions like Alzheimer's disease and other neuropsychiatric disorders. Their commitment extends beyond the laboratory, as they actively engage in clinical trials and seek to translate scientific breakthroughs into tangible treatments accessible to patients worldwide. Suven’s approach leverages a blend of sophisticated analytical tools and a deep understanding of disease mechanisms. They meticulously analyze vast datasets to identify potential drug targets and optimize the development of new chemical entities. This data-driven approach, combined with a strong emphasis on intellectual property and strategic partnerships, allows Suven to navigate the challenging landscape of pharmaceutical development with agility and precision. Their research focuses on identifying innovative solutions that address unmet medical needs, striving to provide effective treatments that can slow down disease progression, alleviate symptoms, and ultimately enhance the quality of life for individuals and families affected by debilitating neurological conditions. Driven by a vision of a healthier future, Suven Life Sciences is committed to fostering a culture of scientific excellence and innovation. Their multifaceted operations encompass drug discovery, clinical development, and strategic commercialization planning, all while maintaining a focus on ethical research practices and patient-centered care. By embracing emerging technologies and continually refining their analytical capabilities, Suven positions itself as a dynamic player in the global healthcare arena, working tirelessly to advance the frontiers of neurological disease treatment and contribute to a more hopeful outlook for those affected by these challenging conditions.
Company Details
Key Leadership
SUVEN Share Price: Frequently Asked Questions
What is the current share price of Suven Life Sciences Limited?
Suven Life Sciences Limited (SUVEN) trades at ₹336.45 on NSE and BSE. Market cap ₹8.88K (Cr). Educational data only.
What is the P/E ratio of Suven Life Sciences Limited?
Suven Life Sciences Limited has a P/E of N/Ax vs industry average 39.78x.
What is the Bull Run score for Suven Life Sciences Limited?
Suven Life Sciences Limited has a Bull Run score of 11.4/100 based on 25+ financial parameters.
Does Suven Life Sciences Limited pay dividends?
Suven Life Sciences Limited has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Suven Life Sciences Limited?
Suven Life Sciences Limited has ROE of -78.80%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Suven Life Sciences Limited?
Suven Life Sciences Limited has debt-to-equity of 0.00.
Is Suven Life Sciences Limited a good investment?
Bull Run gives Suven Life Sciences Limited a score of 11.4/100. This is not investment advice — consult a SEBI-registered advisor.